3 October 2018 - Second FDA fast track designation for AV-101 since December 2017 marks another milestone for VistaGen's R&D pipeline.
VistaGen Therapeutics today announced that the U.S. FDA has granted fast track designation for development of AV-101 as a non-opioid, non-sedating treatment for neuropathic pain. This is the second FDA fast track designation granted to VistaGen since December 2017.
AV-101 is an investigational, orally bioavailable, small molecule NMDA (N-methyl-D-aspartate) receptor glycine B antagonist without psychological or sedative side effects.